Curated News
By: NewsRamp Editorial Staff
December 03, 2025
Oncotelic's IV Everolimus Cuts Gut Toxicity by 67-Fold in New Data
TLDR
- Oncotelic's Sapu003 offers a competitive edge by reducing gastrointestinal side effects up to 67-fold compared to oral everolimus, potentially improving patient compliance and market positioning.
- Oncotelic's intravenous Sapu003 formulation limits gastrointestinal tissue levels to 36-48 times plasma levels, representing a 67-fold reduction from oral dosing's extreme gut exposure of 2,448 times plasma.
- This development could make cancer treatment more tolerable for patients, potentially improving quality of life during therapy and advancing oncology care.
- Oncotelic's new formulation transforms drug delivery, shifting from extreme gut accumulation to targeted systemic exposure while maintaining the drug's metabolic profile.
Impact - Why it Matters
This development matters because it addresses a critical limitation of current cancer therapies. Everolimus is an important drug used to treat various cancers, but its oral formulation often causes severe gastrointestinal side effects—like mouth sores, diarrhea, and nausea—due to excessive drug accumulation in the gut. These side effects can force dose reductions or treatment discontinuations, compromising patient outcomes and quality of life. By dramatically reducing GI exposure through an intravenous formulation, Oncotelic's approach could make everolimus more tolerable, allowing patients to receive full, consistent doses without debilitating side effects. This could improve treatment adherence, potentially enhance survival rates, and set a precedent for reformulating other oncology drugs to minimize toxicity. For the biopharmaceutical industry, it represents an innovative strategy to optimize existing therapies, potentially accelerating development timelines compared to creating entirely new drugs.
Summary
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company with a 45% ownership stake in the Sapu Nano joint venture, has unveiled promising new pharmacokinetic and tissue-distribution data for its investigational drug, Sapu003. This intravenous Deciparticle (TM) formulation of everolimus—a drug used in oncology—demonstrates a dramatic reduction in gastrointestinal drug accumulation compared to the traditional oral version. The data reveals that oral dosing leads to extreme gut exposure, with stomach tissue levels reaching up to 2,448 times that of plasma levels. In stark contrast, intravenous Sapu003 limits gastrointestinal tissue levels to just 36–48 times plasma levels, representing a reduction of up to 67-fold. This significant shift could lead to improved patient tolerability by minimizing gastrointestinal side effects, maintain the drug's intrinsic metabolic profile for consistent therapeutic action, and provide more reliable systemic exposure, potentially enhancing treatment efficacy and safety profiles for cancer patients.
The company, led by CEO Dr. Vuong Trieu—an inventor with over 150 patent applications and 39 issued U.S. patents—focuses on addressing high-unmet-need cancers and rare pediatric indications. Beyond its internal pipeline, Oncotelic strengthens its strategic position through joint ventures like GMP Bio. The full details of this development are available in the press release, which can be accessed via the provided link. This news is distributed through BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which focuses on biotechnology and life sciences sectors, ensuring broad dissemination to investors and the public. For ongoing updates, investors can follow the company’s newsroom.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's IV Everolimus Cuts Gut Toxicity by 67-Fold in New Data
